These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32557296)

  • 1. Understanding the Essentialities in Establishing the Bioequivalence of Oral Inhalation Drug Products to be Marketed in the USA.
    Fernandes SD; Koland M
    Ther Innov Regul Sci; 2020 Jul; 54(4):738-748. PubMed ID: 32557296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of regulations for bioequivalence assessment of locally acting orally inhaled drug products for the United States, Europe, Canada, and India.
    Patil PP; Pawar AP; Mahadik KR; Gaikwad VL
    Expert Opin Drug Deliv; 2021 Dec; 18(12):1843-1855. PubMed ID: 34814778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
    Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
    AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations in establishing bioequivalence of inhaled compounds.
    Mayers I; Bhutani M
    Expert Opin Drug Deliv; 2018 Feb; 15(2):153-162. PubMed ID: 28918665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective.
    Newman B; Babiskin A; Bielski E; Boc S; Dhapare S; Fang L; Feibus K; Kaviratna A; Li BV; Luke MC; Ma T; Spagnola M; Walenga RL; Wang Z; Zhao L; El-Gendy N; Bertha CM; Abd El-Shafy M; Gaglani DK
    Adv Drug Deliv Rev; 2022 Nov; 190():114526. PubMed ID: 36067967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.
    Lee SL; Adams WP; Li BV; Conner DP; Chowdhury BA; Yu LX
    AAPS J; 2009 Sep; 11(3):414-23. PubMed ID: 19495991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes.
    Adams WP; Poochikian G; Taylor AS; Patel RM; Burke GP; Williams RL
    J Aerosol Med; 1994; 7(2):119-34. PubMed ID: 10147277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.
    Newman B; Witzmann K
    Pharmaceut Med; 2020 Apr; 34(2):93-102. PubMed ID: 32112304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD.
    Fuglsang A
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):243-7. PubMed ID: 22857274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for the Forced Expiratory Volume in 1 Second-Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug Products.
    Lee J; Feng K; Conti DS; Walenga R; Wientjes M; Wang H; Newman B; Han L; Dhapare S; Bielski E; Babiskin A; Wu F; Donnelly M; Kim MJ; Jiang W; Luke MC; Fang L; Zhao L
    Clin Pharmacol Ther; 2022 Nov; 112(5):982-989. PubMed ID: 35133652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.
    Lee SL; Saluja B; García-Arieta A; Santos GM; Li Y; Lu S; Hou S; Rebello J; Vaidya A; Gogtay J; Purandare S; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1285-304. PubMed ID: 26002510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union.
    Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K
    Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
    Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
    Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from branded to generic inhaled medications: potential impact on asthma and COPD.
    Lavorini F; Ninane V; Haughney J; Bjermer L; Molimard M; Dekhuijzen RP
    Expert Opin Drug Deliv; 2013 Dec; 10(12):1597-602. PubMed ID: 24224777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dry powder inhaler features of the Easyhaler that benefit the management of patients.
    Chrystyn H; Lavorini F
    Expert Rev Respir Med; 2020 Apr; 14(4):345-351. PubMed ID: 32013627
    [No Abstract]   [Full Text] [Related]  

  • 18. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
    Muralidharan P; Hayes D; Mansour HM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Turbuhaler((R)) in Patients with Acute Airway Obstruction and COPD, and in Children with Asthma : Understanding the Clinical Importance of Adequate Peak Inspiratory Flow, High Lung Deposition, and Low In Vivo Dose Variability.
    Selroos O; Borgström L; Ingelf J
    Treat Respir Med; 2006; 5(5):305-15. PubMed ID: 16928144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Bioequivalence between Generic and Originator Orally Inhaled Drug Products: Validity of Administration of Doses above the Approved Single Maximum Dose.
    Singh GJP; Hickey AJ
    Mol Pharm; 2024 Sep; 21(9):4191-4198. PubMed ID: 39133824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.